GMAB 32.75 ▲ 0.09% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Genmab A/S

    NASDAQ: GMAB · Real-Time Price · USD
    32.75
    0.03 (0.09%)
    At close: Oct 16, 2025, 3:59 PM
    32.50
    -0.76%
    After-hours: Oct 16, 2025, 07:57 PM EDT
    0.09%
    Bid 32
    Market Cap 20.67B
    Revenue (ttm) 22.78B
    Net Income (ttm) 7.44B
    EPS (ttm) 1.93
    PE Ratio (ttm) 16.97
    Forward PE 2.68
    Analyst Buy
    Dividends n/a
    Ask 33.7
    Volume 2,047,596
    Avg. Volume (20D) 1,678,100
    Open 33.19
    Previous Close 32.72
    Day's Range 32.58 - 33.65
    52-Week Range 17.23 - 33.65
    Beta 0.82
    Ex-Dividend Date n/a

    About GMAB

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol GMAB
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for GMAB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Genmab A/S is scheduled to release its earnings on Nov 5, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription
    2 weeks ago
    +3.59%
    Shares of several drugmakers are trading higher af... Unlock content with Pro Subscription
    2 weeks ago
    +0.89%
    GMAB stock has given up its prior loss. Genmab shares were trading lower after the company announced it will acquire Merus for $8 billion.
    news image

    2 days ago · zacks.com

    GMAB or TECH: Which Is the Better Value Stock Right Now?

    Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR (GMAB) and Techne (TECH). But which of these two stocks is more attractive ...

    news image

    1 week ago · zacks.com

    GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal

    Genmab stock surges 21.9% after striking an $8 billion deal to buy Merus, adding a late-stage cancer treatment candidate to its proprietary oncology pipeline.

    news image

    1 week ago · zacks.com

    What Makes Genmab A/S Sponsored ADR (GMAB) a Strong Momentum Stock: Buy Now?

    Does Genmab A/S Sponsored ADR (GMAB) have what it takes to be a top stock pick for momentum investors? Let's find out.

    news image

    1 week ago · zacks.com

    Best Momentum Stock to Buy for October 3rd

    GFI, GMAB and AEG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 3, 2025.

    news image

    1 week ago · zacks.com

    New Strong Buy Stocks for October 3rd

    DORM, AEG, GMAB, SCSC and GFI have been added to the Zacks Rank #1 (Strong Buy) List on October 3rd, 2025.

    news image

    2 weeks ago · businesswire.com

    MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

    NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Merus...

    news image

    2 weeks ago · fool.com

    Why Genmab Stock Was Marching Higher Today

    One day after announcing a sizable acquisition, Denmark-based biotech Genmab (GMAB 4.67%) was doing well on the stock exchange Tuesday. A pair of analysts weighed in with bullish new takes on the comp...

    news image

    2 weeks ago · seekingalpha.com

    Genmab A/S (GMAB) M&A Call Transcript

    Genmab A/S (GMAB) M&A Call September 29, 2025 7:00 AM EDT Company Participants Jan van de Winkel - Co-Founder, President & CEO Tahamtan Ahmadi - Executive VP, Chief Medical Officer & Head of Experimen...

    news image

    2 weeks ago · benzinga.com

    Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough

    Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction re...

    news image

    2 weeks ago · barrons.com

    This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired.

    Genmab will acquire Merus in an all-cash transaction worth around $8 billion.

    Add to Watchlist